<DOC>
	<DOCNO>NCT01341496</DOCNO>
	<brief_summary>Background : - A tumor cell vaccine experimental cancer treatment . Cancer cell collect patient use develop vaccine . The vaccine produce immune system response help destroy cancer cell body . Researchers study way improve tumor cell vaccine . One way add adjuvant . An adjuvant substance brings strong immune system response . ISCOMATRIX adjuvant use safely clinical study . But study certain tumor cell vaccine . Researchers want find whether tumor cell vaccine ISCOMATRIX , give along cancer drug treatment , safe effective way slow prevent tumor growth tumor removal surgery . Objectives : - To assess safety effectiveness tumor cell vaccine give ISCOMATRIX drug therapy tumor removal surgery . Eligibility : - People least 18 year age tumor cell vaccine develop cell take surgically removed tumor . Design : - Patients screen physical examination , medical history , blood urine test , image study . - Patients treat cyclophosphamide ( daily ) celecoxib ( twice daily ) 7 day first vaccine dose . - Patients receive tumor cell vaccine month 6 month . They continue receive drug therapy throughout vaccine treatment . Patients monitor regular blood test image study . - After first 6 month , patient immune response vaccine continue treatment vaccine chemotherapy . They also regular blood test image study . They treatment 24 month first vaccination longer immune response . - Participants followup visit 5 year first vaccination , tumor return .</brief_summary>
	<brief_title>Tumor Cell Vaccines ISCOMATRIX With Chemotherapy After Tumor Removal</brief_title>
	<detailed_description>Background : Cancer-testis ( CT ) antigens ( CTAs ) emerge attractive target cancer immunotherapy . Whereas cancer various histology exhibit CTA expression , primary vaccine-induced immune response antigens appear uncommon patient malignancy , possibly due low-level , heterogeneous antigen expression , inadequate vaccination strategy . Because numerous CT antigen induce tumor cell DNA demethylating agent HDAC inhibitor , conceivable vaccination cancer patient autologous tumor cell expose chromatin remodel agent enhance anti-tumor immunity individual . In order examine issue , patient undergo complete resection sarcoma , melanoma , germ cell tumor epithelial malignancy metastatic lung , pleura mediastinum vaccinate autologous tumor cell expose ex-vivo decitabine radiation follow completion appropriate combine modality therapy . Vaccines administer conjunction ISCOMATRIX adjuvant well metronomic oral cyclophosphamide ( 50 mg PO BID x 7d q 14d ) , celecoxib ( 400 mg PO BID ) . Serologic response variety recombinant CTAs well delay type hypersensitivity autologous epigenetically modified tumor cell assess vaccination . Primary Objective : -To ass safety epigenetically modify autologous tumor cell vaccine administer ISCOMATRIX adjuvant combination metronomic oral cyclophosphamide celecoxib patient undergo thoracic metastasectomy . Eligibility : - Patients histologically cytologically prove clinically evident sarcoma , melanoma , epithelial malignancy metastatic lung , pleura mediastinum render evidence disease ( NED ) metastasectomy . - Patients must 18 year old ECOG performance status 0 2 , without evidence unstable decompensated myocardial disease . Patients must adequate pulmonary reserve evidence FEV1 DLCO equal great 30 % predict ; pCO2 less 50 mm Hg pO2 great 60 mm Hg room air ABG ; immunosuppressive medication except inhaled corticosteroid time vaccination commences . - Patients must platelet count great 100,000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin &lt; 1.5 x upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) time vaccination commences . Design : - Patients undergo thoracic metastasectomy use standard practice guideline . - Portions resect tumor transfer Thoracic Oncology Laboratory . Cells process establish cancer cell line . - Following recovery surgery appropriate adjuvant chemotherapy and/or radiation , patient vaccinate epigenetically-modified autologous tumor cell periodically 6 month conjunction metronomic oral cyclophosphamide celecoxib . - Systemic toxicity delay type hypersensitivity responses autologous tumor cell serologic response variety CT antigens assessed vaccination . - Patients follow routine staging scan disease recurrence . - As exact set comparison analysis perform determine follow completion trial , base limited number patient , analysis consider exploratory hypothesis generate rather definitive . - Approximately 80 patient accrue trial order obtain 20 evaluable patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>INCLUSION CRITERIA : INCLUSION CRITERIA PRIOR TO SURGERY ( SCREENING CONSENT ) : 1 . Patients clinically evident histologically proven sarcoma , melanoma , germ cell tumor , epithelial malignancy metastatic lung , mediastinum , pleura render evidence active disease ( NED ) follow standard surgical therapy . Note : Patients active disease outside thorax may eligible study extrathoracic disease definitively treat local modality radiation , surgery , radiofrequency ablation . 2 . Patients must receive refuse first line standard systemic therapy metastasis . 3 . Patients 3 intracranial metastasis , definitively treat surgery radiation therapy may eligible study provide evidence active disease least 2 month . 4 . Patients must ECOG performance status 0 2 . 5 . Patients must 18 year age old due unknown effect immunologic response germ cellrestricted gene product childhood adolescent development . 6 . Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive decrease immune competence thus may less responsive experimental treatment . 7 . Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . 8 . Patients must aware neoplastic nature illness , experimental nature therapy , alternative treatment , potential benefit , risk . 9 . Patients must willing sign inform consent undergo resection malignancy NCI , ensure vaccine development . INCLUSION CRITERIA FOR TREATMENT PHASE OF PROTOCOL ( Standard Consent ) : 1 . Patients must sign Screening Consent . 2 . NCI Laboratory Pathology confirmation diagnosis sarcoma , melanoma , germ cell tumor , epithelial malignancy metastatic lung , mediastinum , pleura must obtain 3 . Patients initially render NED surgical resection must remain NED time treatment . 4 . Patients 3 intracranial metastasis , definitively treat surgery radiation therapy may eligible study , provide evidence active disease least 2 month requirement anticonvulsant therapy steroid follow treatment . 5 . Patients must ECOG performance status 0 2 . 6 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 8g/dl ( patient may receive transfusion meet parameter PT within 2 second ULN Total bilirubin &lt; 1.5 x upper limit normal Serum creatin ine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m2 . 7 . Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive decrease immune competence thus may less responsive experimental treatment . 8 . Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . 9 . Patients must willing practice birth control four month follow treatment . 10 . Patients must willing sign standard inform consent . EXCLUSION CRITERIA 1 . Patients require corticosteroid ( inhale ) exclude . 2 . Patients life expectancy le 12 month exclude . 3 . Patients receive warfarin anticoagulation , transfer agent enoxaparin dabigatran , anticoagulant hold 24 hour exclude . 4 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated CHF ( &gt; NYHA Class II ) , myocardial infarctionwithin 6 month study exclude . 5 . Patients cardiac disease may exclude discretion PI follow consultation Cardiology consultant . 6 . Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO &lt; 30 % predict ( postbronchodilator ) ; pO2 &lt; 60 % pCO2 ( Bullet ) 50 room air arterial blood gas . 7 . Pregnant and/or lactate woman exclude due unknown , potentially harmful effect immune response CTX antigens stem cell protein may express placenta , fetus , neonate . 8 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 21, 2016</verification_date>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Cancer Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Chest Metastases</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Melanoma</keyword>
</DOC>